1. Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance.
- Author
-
Zhan W, Li D, Subramanyaswamy SB, Liu YJ, Yang C, Zhang H, Harris JC, Wang R, Zhu S, Rocha H, Sherman J, Qin J, Herring M, Simwela NV, Waters AP, Sukenick G, Cui L, Rodriguez A, Deng H, Nathan CF, Kirkman LA, and Lin G
- Subjects
- Animals, Proteasome Endopeptidase Complex metabolism, Pharmacophore, Ubiquitin, Drug Resistance, Antimalarials chemistry, Parasites metabolism, Plasmodium metabolism, Artemisinins pharmacology
- Abstract
Artemisinins (ART) are critical anti-malarials and despite their use in combination therapy, ART-resistant Plasmodium falciparum is spreading globally. To counter ART resistance, we designed artezomibs (ATZs), molecules that link an ART with a proteasome inhibitor (PI) via a non-labile amide bond and hijack parasite's own ubiquitin-proteasome system to create novel anti-malarials in situ. Upon activation of the ART moiety, ATZs covalently attach to and damage multiple parasite proteins, marking them for proteasomal degradation. When damaged proteins enter the proteasome, their attached PIs inhibit protease function, potentiating the parasiticidal action of ART and overcoming ART resistance. Binding of the PI moiety to the proteasome active site is enhanced by distal interactions of the extended attached peptides, providing a mechanism to overcome PI resistance. ATZs have an extra mode of action beyond that of each component, thereby overcoming resistance to both components, while avoiding transient monotherapy seen when individual agents have disparate pharmacokinetic profiles., Competing Interests: Declaration of interests The authors declare the following competing financial interest(s): Cornell University’s Center for Technology Licensing has filed a patent application on these artemisinin proteasome inhibitor hybrids. G. Lin, W. Zhan, H. Zhang, Daqiang Li, C. Nathan, and L. Kirkman are listed as inventors., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF